Physician profile
Joseph A Racanelli
NPI 1801881347
$90,197.44
in general payments reported to CMS, 2019-2025
14 companies · $63K in 2025
The $63K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $672 · 2021: $225 · 2023: $339 · 2024: $13K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $76K · Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,650.00 |
| Food and Beverage | $594.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Royal Biologics, INC. | $75,650.00 | 2024-2025 | Fibrinet, Bio-Reign 3d |
| Miromatrix Medical INC. | $12,060.00 | 2019 | |
| Smith+Nephew, INC. | $823.42 | 2019-2025 | Oasis, Grafix Pl, Stravix Pl |
| Musculoskeletal Transplant Foundation INC. | $587.00 | 2019-2020 | |
| Merz North America, INC. | $271.30 | 2023 | Xeomin |
| Glaxosmithkline, LLC. | $174.91 | 2023-2024 | Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $133.33 | 2021 | |
| Acell, INC. | $124.79 | 2020 | |
| Mentor Worldwide LLC | $122.93 | 2020-2021 | |
| Allergan, INC. | $110.90 | 2019 | |
| Acera Surgical, INC. | $84.88 | 2024-2025 | Restrata Wound Matrix |
| Kerecis Limited | $23.67 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Averitas Pharma INC. | $18.20 | 2025 | Qutenza |
| Tepha INC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Racanelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.